Streetbeat News

TRML

Tourmaline Bio, Inc.

https://www.tourmalinebio.com

Industry

Biotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Open

22.31

Mkt cap

559M

Volume

166K

High

22.34

P/E Ratio

-8.76

52-wk high

48.31

Low

21.23

Div yield

N/A

52-wk low

12.12

Tourmaline Bio, Inc. (NASDAQ: TRML) announced key updates at its Investor Day, including surpassing enrollment targets for its Phase 2 TRANQUILITY trial and nominating a new cardiovascular indication for its drug pacibekitug.

Portfolio Pulse from

December 10, 2024 | 1:45 pm

Tourmaline Bio, Inc. (NASDAQ: TRML) will host a virtual Investor Day on December 10, 2024, featuring presentations from its leadership and Dr. Marc Bonaca. The event aims to provide insights into the company's progress in developing medicines for immune and inflammatory diseases.

Portfolio Pulse from

November 14, 2024 | 12:45 pm

Tourmaline Bio, Inc. reported its Q3 2024 financial results, highlighting a cash position of $314.4 million, which extends its runway into 2027. The company is on track to release Phase 2 trial data in 2025 and has formed a Cardiovascular Scientific Advisory Board.

Portfolio Pulse from

November 07, 2024 | 12:45 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Tourmaline Bio (NASDAQ:TRML) and maintained a price target of $48.